Cabecera 2019 CBMSO CSIC UAM

Wednesday, 18th September 2019
Cell Biology and Immunology
                 Cancer stem cells





Marta Izquierdo Rojo




Research summary:

Nucleostemin is preferentially expressed in stem cells and in several transformed cell lines and tumours, but it is abruptly down-regulated during differentiation to terminal cell fate. We have studied the therapeutic potential of depletion of nucleostemin in cancer stem cells. We used shRNAs (small hairpin RNA) to inhibit nucleostemin in glioma cancer stem cells. We found that one of the shRNAs used (shRNA22), induces apoptosis in CSCs and delays substantially the developing of tumors in vivo. Nevertheless, this RNAi does not deplete the nucleostemin RNA or the corresponding protein. The hypothesis that nucleostemin was not the primary target of shRNA22 motivated the following experiments:

1) We analyzed the genome-wide differentially expressed genes in CSCs-5 after shRNA22 infection, we used Affymetrix GeneChip Gene 1.0 ST Array System containing approximately 28.869 human genes, including the 3' untranslated region (UTR) of the mRNAs that could be a target for binding in a micro (mi)RNA-like manner. The signal transduction pathway with more genes down-regulated was the MAPK kinases pathway. An indication that shRNA22 may be involved in silencing a transcription factor implicated in one of the MAP-kinases signaling-pathways can be suggested although we have no further proof.
2) The shRNA22 could be acting as miRNA. This hypothesis was discharged after consulting the PITA data base, not finding any good match.

New and interesting hypothesis are being consider at present to explain the behavior of shRNA22. Theese will be approached in the near future.


Relevant publications:

  • Gargini, R., García-Escudero, V. and Izquierdo, M. (2011)Therapy mediated by mitophagy abrogates tumor progression.Autophagy 7,466-476.
  • Girald, W., Collin, A. and Izquierdo, M. (2011) Toxicity and delivery methods for the linamarase/linamarin/glucose oxidase system, when used against humanglioma tumors implanted in the brain of nude rats. Cancer Letters 313: 99-107.
  • Gil-Ranedo, J., Mendiburu-Eliçabe, M., García-Villanueva, M., Medina, D., del Álamo, M. and Izquierdo, M.(2011) An off-target nucleostemin RNAi, inhibits growth in human glioblastoma-derived cancer stem cells. PLoS One 6, 12, e28753.
  • klionsky, D.J., Izquierdo, M. et al. (2012)Guidelines for the use and interpretation of assays for monitoring autophagy (revision). Autophagy 8, 1-100.
  • Gil-Ranedo, J., Mendiburu-Eliçabe, M., Izquierdo, M.and Almendral, J.M. (2012) Glioma-parvovirus interactions: molecular insights and therapeutic potential. Capítulo de libro: Glioma/book 3. Novel Therapeutic Concepts in Targeting Glioma,  ISBN:978-953-51-0491-9   Editorial: Tech-Open. Capítulo 8, 144-160.


NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand


What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: